DNALite Therapeutics
San Francisco
About DNALite Therapeutics
DNALite Therapeutics is an early-stage preclinical biotechnology company committed to bringing the next generation of drugs to the gastrointestinal tract. It develops oral lipid nanoparticle technology to deliver mRNA and pDNA into the intestine using the oral route of administration. Its drug aims to use the intestinal tract to secrete proteins into the bloodstream turning any protein biologic into an oral drug.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.3M
- Funding stage: Early Stage Venture
- Last round: Convertible Note (Mar 2023)
- Website: dnalite.com
Industries & Categories
Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/dnalite-therapeutics-59160 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.